# Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

> **NCT00347555** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 80 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria

## Interventions

- **BIOLOGICAL:** Aluminum Phosphate
- **DRUG:** Placebo
- **BIOLOGICAL:** EBA-175 RII-NG Malaria Vaccine

## Key facts

- **NCT ID:** NCT00347555
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00347555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00347555, "Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00347555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*